Loading...

Regeneron COVID-19 antibody therapy cuts death risk in hospitalized patients lacking immune response


Regeneron COVID-19 antibody therapy cuts death risk in hospitalized patients lacking immune response



Regeneron’s COVID-19 therapy was found to reduce the risk of death in hospitalized patients who had not mounted their own immune response to the virus by up to 20%, the company said Wednesday

Health Tips 1410328679097469951

Post a Comment

emo-but-icon

Home item